For decades, venous blood collection has served as the primary method for clinical biomarker analysis. However, the logistics behind this approach, phlebotomy appointments, centralized clinical sites, and temperature-controlled sample transport, can limit participation and increase costs for modern research programs. Dried Blood Spot (DBS) laboratory services enable remote capillary blood collection, where small blood volumes are deposited onto specialized filter paper and transported to laboratories without requiring cold-chain infrastructure. When supported by rigorous laboratory validation, quality control, and regulatory oversight, DBS workflows allow decentralized studies to generate reliable clinical data and improve participant access and operational efficiency.
Validation: Ensuring Scientific Equivalence
Before DBS samples can be used in research or clinical programs, laboratories must validate that biomarker measurements obtained from dried blood spots are comparable to results generated from traditional venous blood samples. Because DBS specimens represent a different analytical matrix than serum or plasma, laboratories must demonstrate that the methods used to collect, extract, analyze DBS samples achieve accurate and reproducible quantification of target analytes. LifeLab1 performs matrix comparison studies in which DBS specimens are examined alongside matched serum or plasma samples. These analyses confirm that DBS measurements reflect the same biological signals typically obtained through conventional venous blood collection.
Several technical parameters guide the validation process:
- Hematocrit variation- Hematocrit influences blood viscosity and determines how blood spreads across filter paper. Differences in hematocrit can affect spot size, analyte distribution, and measurement accuracy. LifeLab1 addresses this challenge through direct hematocrit measurement using automated technology, ensuring accurate and reliable results across populations with varying hematocrit levels.
- Extraction performance- Validation evaluates the efficiency and consistency of analyte recovery from the filter paper matrix. Recovery rates and concentration linearity are measured to confirm that extracted biomarker levels accurately reflect their concentrations in the original blood sample.
- Analyte stability- DBS samples may encounter temperature fluctuations during transport, particularly in international research programs. LifeLab1 assesses analyte stability under a range of environmental and storage conditions to verify that biomarkers remain stable throughout shipping and handling.
- Analytical sensitivity- High-sensitivity Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) platforms used by LifeLab1 provide the analytical sensitivity required to quantify multiple biomarkers from a blood spot while maintaining strong analytical precision. This capability supports dependable biomarker analysis from very small sample volumes.
These parameters for validation ensure that DBS samples can be processed and analyzed consistently through LifeLab1’s dried blood spot laboratory services. Once validated, DBS workflows allow specimens collected outside traditional clinical settings to be integrated into laboratory testing pipelines without compromising data quality. This approach allows research and clinical programs to incorporate remote sample collection and still generate reliable biomarker measurements for study analysis and clinical reporting.
Quality Control: Maintaining Data Integrity
Following method validation, quality control procedures ensure that every DBS sample processed through LifeLab1’s DBS laboratory services meets established analytical standards. For research studies and clinical programs that depend on DBS sampling, consistent sample integrity and measurement accuracy are crucial when obtaining reliable biomarker data.
Quality oversight begins during the pre-analytical inspection of DBS cards. Before analysis, each DBS card is inspected for issues such as clotting, uneven spreading, insufficient volume, or oversaturation. Samples that do not meet acceptance criteria are excluded to ensure reliable results.
As part of analytical testing, several quality control mechanisms preserve consistency across sample batches within LifeLab1’s DBS laboratory workflows, supporting accurate biomarker quantification for research and clinical applications. They include:
- Automated DBS punching systems- produce standardized sample discs and reduce manual handling variability.
- Isotopically labeled internal standards- monitor extraction efficiency and instrument performance through each analytical run.
- Batch-level control samples- verify assay performance and calibration across testing batches.
Traceability is equally important. LifeLab1 uses a laboratory information management system (LIMS) to trace DBS samples throughout the testing workflow. The system records key stages including kit registration, sample receipt, laboratory processing, analytical testing, and result reporting. This record allows every DBS sample used in research studies and clinical programs to be traced from collections through to final analytical data, forming an audit trail that supports reproducibility, regulatory documentation, and peer-reviewed research.
Regulatory Considerations for Research and Clinical Programs
DBS laboratory services utilized for research studies and clinical programs must operate within established regulatory frameworks to ensure reliable analytical data and protect study participants. LifeLab1 operates in line with ISO 15189 principles, which define quality and competence requirements for medical laboratories. Such standards call for laboratories to validate analytical assays, implement documented quality management procedures, and maintain traceable records for sample handling, testing, and result reporting. Adhering to these standards ensures DBS laboratory services enabling research studies and clinical programs are performed within a controlled and compliant laboratory environment.
In addition to laboratory standards, broader regulatory frameworks influence how DBS-based testing is implemented, particularly when assays or workflows involve in vitro diagnostic (IVD) components. The In Vitro Diagnostic Regulation (IVDR 2017/746) establishes requirements for the development, performance, and conformity assessment of IVD medical devices within Europe, instead of governing laboratory services in their entirety. For DBS workflows, this means that any associated diagnostic assays, reagents, or instruments must meet IVDR criteria where applicable. Aligning with IVDR requirements enables research partners to integrate validated diagnostic components into their studies, while maintaining the analytical standards expected for clinical research.
Data protection is another key consideration. LifeLab1 maintains GDPR-compliant data handling practices to protect participant privacy and enable responsible research data management. Defining the intended use of DBS testing is fundamental, as some programs operate under research-use-only frameworks whereas others require diagnostic validation pathways.
LifeLab1 DBS Laboratory Services for Research and Clinical Programs
Reliable DBS testing necessitates robust laboratory workflows, including validated DBS extraction protocols, matrix comparison studies with venous samples, and high-sensitivity LC-MS/MS for biomarker quantification. LifeLab1 delivers scalable solutions for clinical trials, cohort studies, and population health research, including standardized DBS collection kits and remote sample collection systems, as well as LC-MS/MS biomarker analysis. Contact LifeLab1 today to discuss how our DBS collection and testing services can support your next clinical study.
